The main pathogenetic mechanisms of vascular cerebral pathology associated with atherosclerosis and metabolic syndrome: the search for correction approaches

Cover Page

Abstract

Metabolic syndrome (MS) is a risk factor for the development of acute and chronic vascular diseases of the brain. Oxidative stress developing under these conditions promotes the progression of atherosclerotic disease of the brachiocephalic arteries, which necessitates correction of the identified pathobiochemical abnormalities. The use of antioxidant drugs in patients with cerebrovascular diseases and MS reduces manifestations of the latter, including insulin resistance, hypertriglyceridemia, and hyperglycemia. The article presents the results of investigation of the drug mexidol in patients with chronic cerebrovascular diseases associated with atherosclerosis and MS. The findings demonstrate that drugs of this group have good prospects to be used for comprehensive correction of various pathogenic stages of the developing pathology.

About the authors

M. M. Tanashyan

Research Center of Neurology, Moscow

Author for correspondence.
Email: platonova@neurology.ru
Russian Federation

O. V. Lagoda

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

K. V. Antonova

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

A. A. Raskurazhev

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

References

  1. Антонова К.В. Влияние антиоксидантной терапии на показатели окислительного стресса. Автореф. дисс. канд. мед. наук. М., 2008.
  2. Ануфриев П.Л., Танашян М.М., Гулевская Т.С. и др. Особенности атеросклероза церебральных артерий и патоморфологии инфарктов головного мозга при сахарном диабете 2 типа. Анн. клин.и эксперим. неврол. 2015; 5: 4–9.
  3. Стаховская Л.В., Клочихина О.А., Богатырева М.Д, Коваленко В.В. Эпидемиология инсульта в России по результатам территориально-популяционного регистра (2009–2010). Журн. неврол. и психиатрии им. С.С. Корсакова. 2013; 5: 4–10.
  4. Суслина З.А., Танашян М.М., Ионова В.Г. Ишемический инсульт: кровь, сосудистая стенка и антитромботическая терапия. М.: Медицинская книга, 2005.
  5. Суслина З.А., Варакин Ю.Я. Эпидемиологические аспекты изучения инсульта. Время подводить итоги. Анн. клин. и эксперим. неврол. 2007; 1: 22–28.
  6. Танашян М.М., Лагода О.В., Гулевская Т.С. и др. Клинико-морфологические и биохимические маркеры прогрессирования атеросклероза. Журн. неврол. им. Б.М. Маньковского. 2013; 1: 38–42.
  7. Танашян М.М., Максюткина Л.Н., Лагода О.В. и др. Цереброваскулярные заболевания и каротидный атеросклероз: биомаркеры воспаления и коагуляции. Клин. неврол. 2013; 3: 16–23.
  8. Танашян М.М., Раскуражев А.А., Шабалина А.А. и др. Биомаркеры церебрального атеросклероза: возможности ранней диагностики и прогнозирования индивидуального риска. Анн. клин.и эксперим. неврол. 2015; 3: 20–25.
  9. Abbasi F., Asagmi T., Cooke J.P. et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am. J. Cardiol. 2001; 88: 1201–1203.
  10. Boden-Albala B., Sacco R.L., Lee H.S. Metabolic syndrome and ischemic stroke risk: Northern Manhattan study. Stroke. 2008; 39: 30–35.
  11. Boger R.H., Bode-Boger S.M., Szuba A. et al. Asymmetric dimethylarginine (АДМА): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842–1847.
  12. Feigin V.L., Forouzanfar M.H., Krishnamurthi R. et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014; 383 (9913): 245–254.
  13. Hu G., Sarti C., Jousilahti P. et al. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke. 2005; 36: 2538–2543.
  14. Kawamoto R., Tomita H., Oka Y. et al. Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis. Intern. Med. 2005; 44: 1232–1238.
  15. Maksimovic M., Vlajinac H., Radak D. et al. Frequency and characteristics of metabolic syndrome in patients with symptomatic carotid atherosclerosis. Rev. Med. Chile. 2009; 137: 329–336.
  16. Miyazaki H., Matsuoka H., Cooke J.P. et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999; 99: 1141–1146.
  17. Muniyappa R., Iantorno M., Quon M.J. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol. Metab. Clin. North Am. 2008; 37: 685–711.
  18. Okazaki S., Sakaguchi M., Miwa K. et al. Association of interleukin-6 with the progression of carotid atherosclerosis: a 9-year follow-up study. Stroke. 2014; 45: 2924–2929.
  19. Palmer С., Kimber Ch., Doney A. Combined effect of inflammatory gene polymorphisms and the risk of ischemic stroke in a prospective cohort of subjects with type 2 diabetes: A Go-DARTS Study. Diabetes.2010; 59; 2945–2948.
  20. Rundek T., White H., Boden-Albala B. et al. The metabolic syndrome and subclinical carotid atherosclerosis: the Northern Manhattan Study. J. Cardiometab. Syndr. 2007; 2: 24–29.
  21. Smith C.L., Anthony S., Hubank M. et al. Effects of АДМА upon gene expression: an insight into the pathophysiological significance of raised plasma АДМА. PLoS Med. 2005; 10: 1031–1043.
  22. Yang Z.C., Wang K.S., Wu Y. et al. Asymmetric dimethylarginine impairs glucose utilization via ROS/TLR4 pathway in adipocytes: an effect prevented by vitamin E. Cell Physiol. Biochem. 2009; 24: 115–124.
  23. Zoccali C. Asymmetric dimethylarginine (АДМА): a cardiovascular and renal risk factor on the move. J. Hypertens. 2006; 24: 611–619.

Statistics

Views

Abstract: 1188

PDF (Russian): 679

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) 2016 Tanashyan M.M., Lagoda O.V., Antonova K.V., Raskurazhev A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies